CareDx has agreed to accumulate Naveris in a deal value as much as $260m, priming the corporate to inherit a blood‑based mostly monitoring answer for viral‑mediated cancers.
CareDx’s deal for the precision oncology diagnostics firm is structured with an upfront money fee of $160m, with the potential for an extra $100m pending income milestones. CareDx and Naveris anticipate the transaction to shut in Q3 2026.
Naveris’s lead product is NavDx, a liquid biopsy platform based mostly on tumour tissue modified viral (TTMV) DNA. The take a look at measures fragments of viral DNA launched from tumour tissue into the bloodstream and serves as a biomarker in human papillomavirus (HPV)‑pushed cancers.
Designed for tumour‑naïve testing and affected person administration from prognosis by publish‑remedy molecular residual illness (MRD) surveillance, NavDx obtained Medicare protection in 2023. Based on Naveris, the Massachusetts-based firm has carried out 130,000 industrial exams with NavDx to this point.
In CareDx’s Q1 2026 financials, launched on 28 April, the corporate’s testing providers section reported income of $91m, comparable to a 48% year-over-year (YoY) uptick. CareDx reported income of $16m for its affected person and digital options section versus $12m in the identical interval of 2025.
In the meantime, CareDx introduced plans to divest its lab products business to EuroBio Scientific in a $170m deal on 15 April. In Q1, CareDx mentioned this section was “comparatively flat”, declining by 4% YoY to $10m.
CareDx’s choice to promote its lab merchandise enterprise follows an analogous transfer by Thermo Fisher this week to promote its microbiology business to Astorg in a deal above $1bnsuggesting a pattern of strategic realignment for some gamers concerned within the diagnostics house.
CareDx CEO John Hanna anticipates that the acquisition of Naveris will speed up its technique to advance the expansion of its precision medication testing providers and affected person and digital options enterprise segments.
Commenting on the deal, Hanna mentioned: “We’re targeted on being a frontrunner in concentrated speciality markets the place a excessive burden of illness drives repeat testing. Naveris suits that profile with a differentiated expertise that’s early in its adoption.
“Naveris is poised for robust development, leveraging our core capabilities – constructing perception in molecular testing, simplifying scientific workflow, and producing proof for protection and reimbursement.”
Naveris CEO, James McNally, commented: “We’re thrilled to be combining forces with CareDx to fulfil our mission of bettering affected person outcomes by delivering disruptive expertise that transforms most cancers care and increasing affected person entry to precision medication.”
